INVO Stock Overview
Together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
INVO Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.86 |
| 52 Week High | US$8.60 |
| 52 Week Low | US$0.50 |
| Beta | 1.49 |
| 1 Month Change | -7.02% |
| 3 Month Change | -26.50% |
| 1 Year Change | -78.50% |
| 3 Year Change | -99.03% |
| 5 Year Change | -99.62% |
| Change since IPO | -99.92% |
Recent News & Updates
Shareholder Returns
| INVO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.4% | -0.8% | -0.6% |
| 1Y | -78.5% | 1.9% | 22.5% |
Return vs Industry: INVO underperformed the US Medical Equipment industry which returned 1.9% over the past year.
Return vs Market: INVO underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| INVO volatility | |
|---|---|
| INVO Average Weekly Movement | 42.7% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: INVO's share price has been volatile over the past 3 months.
Volatility Over Time: INVO's weekly volatility has decreased from 51% to 43% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 28 | Steve Shum | www.invobioscience.com |
INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.
INVO Bioscience, Inc. Fundamentals Summary
| INVO fundamental statistics | |
|---|---|
| Market cap | US$3.28m |
| Earnings (TTM) | -US$7.08m |
| Revenue (TTM) | US$4.25m |
0.8x
P/S Ratio-0.5x
P/E RatioIs INVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INVO income statement (TTM) | |
|---|---|
| Revenue | US$4.25m |
| Cost of Revenue | US$2.55m |
| Gross Profit | US$1.70m |
| Other Expenses | US$8.78m |
| Earnings | -US$7.08m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.86 |
| Gross Margin | 39.90% |
| Net Profit Margin | -166.64% |
| Debt/Equity Ratio | 28,452.2% |
How did INVO perform over the long term?
See historical performance and comparison